Want to see SE:SYNACT full AI Analyst Report?
SYNACT Stock Chart & Stats
kr18.48
-kr0.02(-0.11%)
At close: 4:00 PM EDT
kr18.48
-kr0.02(-0.11%)
Day’s Range― - ―
52-Week Rangekr7.05 - kr25.30
Previous CloseN/A
Volume64.35K
Average Volume (3M)214.83K
Market Cap
kr1.06B
Enterprise Valuekr913.67
Total Cash (Recent Filing)kr65.78M
Total Debt (Recent Filing)kr1.07M
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding53,330,242
10 Day Avg. Volume154,831
30 Day Avg. Volume214,829
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)6.78
Price to Sales (P/S)0.00
P/FCF Ratio-11.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Sizable Equity BufferA very low debt-to-equity ratio and a meaningful equity base provide durable solvency protection and strategic optionality. This reduces near-term insolvency risk and gives management flexibility to fund R&D and clinical programs without immediate reliance on high-cost debt, supporting run-rate operations while programs advance.
Focused Clinical-stage Lead CandidateA concentrated R&D focus on resomelagon (AP1189) and a clear mechanism (melanocortin-mediated resolution of inflammation) is a durable strategic asset. Concentration of resources into a differentiated, mechanism-driven program can accelerate development, clarify regulatory pathways, and create high-value upside if clinical milestones are achieved.
Targeting Chronic Inflammatory And Autoimmune DiseasesOperating in large, structurally durable markets like rheumatoid arthritis offers sustained demand if clinical efficacy is demonstrated. Successful positioning in chronic inflammatory indications enables multi-indication expansion and recurring revenue potential, making the commercial opportunity long-lived versus one-off markets.
Bears Say
Zero Revenue And Large Net LossesThe company remains pre-revenue with persistent, substantial net losses, which is a fundamental risk. Long-term viability depends on binary clinical outcomes or recurrent financing; absent revenue, continued losses erode equity and leave the business highly sensitive to trial delays, failure, or funding gaps.
Consistent Negative Operating And Free Cash FlowMaterial negative operating and free cash flow indicate ongoing cash burn to support R&D and operations. While TTM shows some improvement versus 2025, sustained negative FCF increases reliance on external financing, raising dilution and execution risk and constraining strategic choices over the medium term.
Negative Returns On Equity (ROE)A deeply negative ROE signals persistent value destruction and poor capital efficiency. Over time this pressures management to alter strategy, raise capital, or cut spending; without a path to profitability, negative ROE undermines shareholder value and increases the risk of dilutive financing or asset repricing.
SynAct Pharma AB News
SYNACT FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
SynAct Pharma AB lowest stock price was kr7.05 and its highest was kr25.30 in the past 12 months.
What is SynAct Pharma AB’s market cap?
SynAct Pharma AB’s market cap is kr1.06B.
When is SynAct Pharma AB’s upcoming earnings report date?
SynAct Pharma AB’s upcoming earnings report date is Aug 20, 2026 which is in 3 days.
How were SynAct Pharma AB’s earnings last quarter?
SynAct Pharma AB released its earnings results on May 27, 2026. The company reported -kr0.476 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is SynAct Pharma AB overvalued?
According to Wall Street analysts SynAct Pharma AB’s price is currently Overvalued.
Does SynAct Pharma AB pay dividends?
SynAct Pharma AB does not currently pay dividends.
What is SynAct Pharma AB’s EPS estimate?
SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SynAct Pharma AB have?
SynAct Pharma AB has 53,330,242 shares outstanding.
What happened to SynAct Pharma AB’s price movement after its last earnings report?
SynAct Pharma AB reported an EPS of -kr0.476 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.848%.
Which hedge fund is a major shareholder of SynAct Pharma AB?
Currently, no hedge funds are holding shares in SE:SYNACT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SynAct Pharma AB
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
Technical Analysis
Oncopeptides AB
―
Saniona AB
―
Ascelia Pharma AB
―
Guard Therapeutics International AB
―
Cantargia AB
―